Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has been given an average rating of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.00.
Several research firms have issued reports on OSMT. BidaskClub cut Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Wells Fargo & Company reissued a “hold” rating on shares of Osmotica Pharmaceuticals in a research note on Thursday, September 3rd. SVB Leerink raised their target price on Osmotica Pharmaceuticals from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Zacks Investment Research cut Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, SunTrust Banks raised their target price on Osmotica Pharmaceuticals from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, July 10th.
Shares of NASDAQ:OSMT traded up $0.07 during midday trading on Friday, hitting $5.98. The company had a trading volume of 188,141 shares, compared to its average volume of 405,853. Osmotica Pharmaceuticals has a twelve month low of $2.81 and a twelve month high of $9.67. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.17 and a quick ratio of 2.83. The stock has a market cap of $308.09 million, a price-to-earnings ratio of -2.04 and a beta of 3.31. The business’s 50-day simple moving average is $5.50 and its 200-day simple moving average is $5.33.
Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Osmotica Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 28,642 shares of the company’s stock valued at $192,000 after buying an additional 6,312 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Osmotica Pharmaceuticals in the first quarter valued at $52,000. Meeder Asset Management Inc. grew its stake in shares of Osmotica Pharmaceuticals by 47.2% in the first quarter. Meeder Asset Management Inc. now owns 11,216 shares of the company’s stock valued at $35,000 after buying an additional 3,597 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Osmotica Pharmaceuticals by 47.9% in the first quarter. Geode Capital Management LLC now owns 203,984 shares of the company’s stock valued at $648,000 after buying an additional 66,058 shares in the last quarter. Finally, State of Tennessee Treasury Department boosted its holdings in Osmotica Pharmaceuticals by 175.3% in the first quarter. State of Tennessee Treasury Department now owns 10,149 shares of the company’s stock valued at $32,000 after purchasing an additional 6,463 shares during the period. 11.89% of the stock is owned by institutional investors and hedge funds.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.